Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Vanderbilt University |
---|---|
Information provided by: | Vanderbilt University |
ClinicalTrials.gov Identifier: | NCT00656032 |
The broad goal of this study is to understand the mechanisms by which Vitamin D receptor activation leads to changes in insulin signaling in advanced uremia. We hypothesize that 1,25-Dihydroxyvitamin D3 deficiency due to advanced chronic kidney disease leads to insulin resistance and that administration of a vitamin D3 analog will restore insulin sensitivity in End Stage Renal Disease patients.
Condition | Intervention | Phase |
---|---|---|
End Stage Renal Disease |
Drug: paricalcitol Drug: cinacalcet |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Vitamin D, Insulin Resistance and Inflammation in ESRD |
Estimated Enrollment: | 12 |
Study Start Date: | April 2008 |
Estimated Study Completion Date: | December 2012 |
Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator |
Drug: paricalcitol
1 to 20 micrograms administered via IV; every other day, 3 days per week, for 8 weeks
|
2: Active Comparator |
Drug: cinacalcet
0 to 180 mg administered orally every day for either 8 weeks or 16 weeks
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Mary Sundell | 615-322-4698 | mary.b.sundell@vanderbilt.edu |
United States, Tennessee | |
Vanderbilt University Medical Center | Recruiting |
Nashville, Tennessee, United States, 37232 | |
Contact: Mary Sundell 615-322-4698 mary.b.sundell@vanderbilt.edu | |
Principal Investigator: Alp Ikizler, MD |
Principal Investigator: | Alp Ikizler, MD | Vanderbilt University |
Responsible Party: | Vanderbilt University Medical Center ( T. Alp Ikizler, MD ) |
Study ID Numbers: | 080074 |
Study First Received: | April 4, 2008 |
Last Updated: | December 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00656032 |
Health Authority: | United States: Institutional Review Board |
insulin resistance end stage renal disease |
Renal Insufficiency Metabolic Diseases Kidney Failure, Chronic Ergocalciferols Insulin Inflammation Hyperinsulinism Vitamin D |
Urologic Diseases Renal Insufficiency, Chronic Kidney Diseases Insulin Resistance Glucose Metabolism Disorders Metabolic disorder Kidney Failure |
Pathologic Processes |